Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Measles Claims Life of Unvaccinated Texas Schoolchild, First US Fatality Reported Since 2015
A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.
Would you Know Measles if You Saw It?
A case of measles is a very rare diagnosis in the 21st century, but as MMR vaccination rates fall, the cases climb. Would you recognize the signs & symptoms?
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
Your daily dose of the clinical news you may have missed.
Home-Based Therapy Achieves 100% Success Rate in Children with High-Threshold Peanut Allergy
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI
Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.
This is Measles If You've Never Seen It
Here, the 5 key signs and symptoms that characterize measles in the order of appearance.
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.
Arcutis Announces Positive Phase 3 Data on Roflumilast Cream 0.05% for Atopic Dermatitis in Young Children
Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.
FDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care Use
The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.
FDA Approves Expanded Use for Sublocade for Opioid Use Disorder
These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.
Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.
Depression Increases Risk For and Accrual of Long-Term Health Disorders
Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.
Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.
Cancer Rates in Black Individuals Decline but Still Outpace Other Racial, Ethnic Groups, Says American Cancer Society
The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.
FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis
The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.
5 Final Dermatology Tips from the Midwinter Hawaii Dermatology Conference
Tips cover biologic agents and hepatitis B, 5-FU plus calcipotriene for AK, a triple treatment package for post-acne postinflammatory hyperpigmentation, and more.
Advancements in Actinic Keratosis Management: Expert Insights from the 2025 Winter Clinical Dermatology Conference
Neal Bhatia, MD, highlighted updates in the management of actinic keratosis, emphasizing strategies to reduce skin cancer risk and improve patient outcomes.
Key Developments in Cosmeceuticals: Highlights from the Midwinter Clinical Hawaii Derm Conference
Cheri Frey, MD, explored novel active ingredients, advancements in skin care formulations at the Midwinter Clinical Derm Conference.